Clinicopathological and immunohistochemical analysis of 20 cases of Merkel cell carcinoma in search of prognostic markers
Article first published online: 26 APR 2005
Volume 46, Issue 6, pages 622–634, June 2005
How to Cite
Llombart, B., Monteagudo, C., López-Guerrero, J. A., Carda, C., Jorda, E., Sanmartín, O., Almenar, S., Molina, I., Martín, J. M. and Llombart-Bosch, A. (2005), Clinicopathological and immunohistochemical analysis of 20 cases of Merkel cell carcinoma in search of prognostic markers. Histopathology, 46: 622–634. doi: 10.1111/j.1365-2559.2005.02158.x
- Issue published online: 18 MAY 2005
- Article first published online: 26 APR 2005
- Date of submission 30 November 2004 Accepted for publication 7 January 2005
- cutaneous neuroendocrine carcinoma;
- Merkel cell carcinoma;
- prognostic factors;
Aims: To evaluate the clinicopathological and immunohistochemical characteristics of Merkel cell carcinoma (MCC) in an attempt to find new, potentially significant, prognostic markers.
Methods and results: Clinical data and follow-up, histopathological features (pattern, cell size, thickness, mitoses, vascular invasion, lymphocytic infiltration) and immunohistochemical detection [CK20, thyroid transcription factor (TTF-1), chromogranin A, synaptophysin, p53, Ki67, Fli-1, CD99, c-Kit] were evaluated in 20 cases of MCC. Fli-1 and CD99 were detected in 90% and 55% of cases, respectively. Tumour size > 30 mm, stage II, ‘absent’ lymphocytic infiltration, and the presence of > 50% of Ki67+ tumour cells, were found to be prognostic indicators of disease-free interval (DFI), but only ‘absent’ lymphocytic infiltration constituted an independent prognostic factor of DFI after multivariate analysis. For overall survival, the same variables, together with local recurrence and lymph node involvement, had prognostic significance, with only local recurrence as an independent prognostic factor after multivariate analysis.
Conclusions: Absence of lymphocytic infiltration and Ki67 immunoreactivity in more than 50% of tumour cells should be evaluated in conjunction with other well-known prognostic markers in MCC. Furthermore, recognizing that Fli-1 and CD99 expression is commonly found in MCC by immunohistochemistry may avoid misinterpretation in the differential diagnosis of MCC with other small round cell tumours.